Ms. Xin Xin | Cancer Biomarkers | Best Researcher Award

Posted on by Pencis

Ms. Xin Xin | Cancer Biomarkers | Best Researcher Award

Shanghai University of Traditional Chinese Medicine | China

AUTHOR PROFILE

Scopus

šŸ“š EARLY ACADEMIC PURSUITS

Xin Xinā€™s academic journey is rooted in the integration of Traditional Chinese Medicine (TCM) with Western medicine, particularly focusing on reproductive health and gynecology. He obtained a Bachelor of Science in Chinese Medicine from Shandong University of Traditional Chinese Medicine. His academic foundation continued to expand as he pursued an MD in Gynecology of Traditional Chinese Medicine, further honing his expertise in reproductive diseases. Xin is currently working towards his PhD in Clinical Chinese Medicine Integrated with Western Medicine at Shanghai University of Traditional Chinese Medicine, under the guidance of Advisor Jinfu Zhang.

šŸ’¼ PROFESSIONAL ENDEAVORS

Xin Xinā€™s professional career is centered on bridging the gap between traditional and modern medical approaches. He is particularly involved in the clinical and mechanistic research of reproductive diseases, with a primary focus on polycystic ovary syndrome (PCOS). His work aims to enhance diagnostic methods and treatment approaches through a combined understanding of TCM and Western medicine. Xin has contributed significantly to clinical studies and investigations, with his academic path guided by prominent scholars in the field, including Dr. Fang Lian and Dr. Haicui Wu during his MD program at Shandong University.

šŸ”¬ CONTRIBUTIONS AND RESEARCH FOCUS ON CANCER BIOMARKERS

Xin Xinā€™s research is notable for its emphasis on the pathogenesis, diagnosis, and treatment of reproductive diseases, with a particular focus on PCOS. He has undertaken several groundbreaking projects, one of which explores the expression of long non-coding RNAs (lncRNA) in follicular fluid exosomes of patients with obesity and PCOS using high-throughput sequencing technology. This research represents an effort to better understand the molecular mechanisms behind PCOS and to uncover novel biomarkers for early detection and intervention.

Another area of Xinā€™s research explores the role of Bone Morphogenetic Protein 6 (BMP6) in regulating Pentraxin 3 expression in human granulosa lutein cells in women with PCOS. His studies are pivotal in uncovering molecular markers and pathways that could lead to more effective therapeutic strategies.

šŸŒŸ IMPACT AND INFLUENCE

Xin Xin’s work has garnered attention within the scientific community due to his innovative approach of combining traditional Chinese medicine with Western medical techniques. His research aims to contribute to the development of a more holistic and comprehensive understanding of reproductive diseases. By investigating both the molecular and clinical aspects of PCOS, Xin is pushing boundaries in reproductive health research. His work has the potential to change how clinicians approach the treatment of polycystic ovary syndrome, a condition that affects millions of women worldwide.

šŸ“‘ ACADEMIC CITES

Although his research is relatively recent, Xin Xinā€™s work is beginning to attract attention in the academic community. His publications on the expression of lncRNAs and BMP6 in PCOS are contributing to the growing body of knowledge on this common reproductive disorder. These publications are expected to increase in citations as they influence future studies and clinical approaches. His articles, including ā€œExploring lncRNA expression in follicular fluid exosomes of patients with obesity and polycystic ovary syndromeā€ (2024), and ā€œBone Morphogenetic Protein 6 Induces Downregulation of Pentraxin 3 Expression in Human Granulosa Lutein Cells in Women With Polycystic Ovary Syndromeā€ (2024), are already making a mark in reproductive health research.

šŸŒ± LEGACY AND FUTURE CONTRIBUTIONS

Looking ahead, Xin Xin is poised to continue his impactful contributions to the field of reproductive medicine. With a focus on integrating TCM with Western medical practices, his future research may lead to the development of novel therapeutic modalities for PCOS and other reproductive diseases. He is likely to remain an influential figure in the field of gynecology, particularly in areas that explore the intersections between traditional and modern approaches to healthcare. His research has the potential to influence both clinical practices and medical education, paving the way for new, more integrated methods of treating complex reproductive health conditions.

In the coming years, Xin Xinā€™s work will likely expand into further clinical trials and studies, contributing to the refinement of treatments for women with PCOS, and potentially providing a more personalized and effective approach to reproductive medicine globally.

āœØConclusion:

Xin Xin’s academic and professional journey stands as a testament to the growing importance of integrating traditional and modern medical practices in addressing complex health conditions. His dedicated research in reproductive medicine, particularly focusing on polycystic ovary syndrome (PCOS), has already made valuable contributions to understanding its pathogenesis and improving diagnostic and therapeutic methods. By exploring innovative molecular mechanisms and combining high-throughput sequencing technology with traditional Chinese medicine, Xin is laying the groundwork for a more holistic approach to treating reproductive diseases.

šŸ“ŠšŸ”¬NOTABLE PUBLICATION:
  • Reproductive outcomes of dual trigger with combination GnRH agonist and hCG versus trigger with hCG alone in women undergoing IVF/ICSI cycles: a retrospective cohort study with propensity score matching
    • Authors: Dong, L., Lian, F., Wu, H., Yu, X., Xin, X.
    • Journal: BMC Pregnancy and Childbirth
    • Year: 2022

 

  • The effect of large follicle puncture and aspiration on the outcomes of IVF-ET in patients with asynchronized follicles under the long GnRH-a protocol: a retrospective cohort study
    • Authors: Wang, Y., Pang, C., Wu, H., Xin, X., Lian, F.
    • Journal: BMC Pregnancy and Childbirth
    • Year: 2023

 

  • Effect of human chorionic gonadotropin injection before frozen-thawed embryo transfer: A retrospective cohort study
    • Authors: Xin, X., Dong, L., Guan, L., Li, J., Lian, F.
    • Journal: Medicine (United States)
    • Year: 2023

 

  • Clinical Efficacy and Mechanism of Erzhi Tiangui Prescription in Treatment of Patients with Repeated Implantation Failure of Kidney Deficiency Syndrome Based on sPD-1 and Th17/Treg Cytokines
    • Authors: Wang, Y., Pang, C., Wu, H., Xin, X., Lian, F.
    • Journal: Chinese Journal of Experimental Traditional Medical Formulae
    • Year: 2023

 

  • Total knee arthroplasty in patients with Klippel Trenaunay syndrome and knee osteoarthritis: A case report and a literature review
    • Authors: Li, J., Lv, G., Han, Z., Xin, X.
    • Journal: Medicine (United States)
    • Year: 2024

Dr. Honghong Zhu | Colorectal Cancer | Best Researcher Award

Posted on by Pencis

Dr. Honghong Zhu | Colorectal Cancer | Best Researcher Award

Zhejiang Chinese Medical University | China

Author Profile

Scopus

Biography of Hong-Hong Zhu, MD, MSc, PhD ā€“ Professor of Extraordinary Ability šŸŽ“šŸŒ

šŸŽÆ Current Role: Leader in Medical Research

Dr. Hong-Hong Zhu is the Head of the Center for Medical Research at Zhejiang Chinese Medical University Affiliated Four-Province-Bordering Hospital of Traditional Chinese Medicine (Quzhou Hospital of TCM). Her leadership in medical research spans over three decades.

šŸ“œ Educational Background

  • Ph.D. in Epidemiology from Johns Hopkins University (JHU) Bloomberg School of Public Health (2007)
  • Postdoctoral Training at the U.S. National Institutes of Health (NIH)
  • MD & Masterā€™s Degree in Medicine from Zhejiang University
  • M.Sc. from Clemson University

šŸ’” Key Contributions: Breast Cancer Etiology Pioneer

Dr. Zhu was the first to propose the Synergistic Interaction Theory for breast cancer, linking environmental carcinogens and exogenous hormone use. Her work has significantly advanced the understanding of cancer causes.

šŸ”¬ Innovator in Colorectal Cancer Prevention

With 32 years of research in colorectal cancer prevention, Dr. Zhu and her team developed cost-effective screening methods that have saved millions of lives worldwide.

šŸ† Academic Achievements and Awards

  • 135 Publications in esteemed journals
  • 35 Awards, including:
    • Best Poster Award (NIH) for breast cancer research (2006)
    • Delta Omega Honor from the U.S. National Public Health Honor Society (2007)
    • Second Place in Scientific Competition in Epidemiology and Public Health (2007)
    • Professor of Extraordinary Ability (2015)
    • Sigma Xi Scientific Research Honor (2024)

šŸ“š Editor and Peer Reviewer

  • Editor-in-Chief of the Journal of GHR (since 2015)
  • Peer Reviewer for academic journals for over 20 years
  • Grant Reviewer for the U.S. Department of Health and Human Services (12 years)

Dr. Hong-Hong Zhu’s contributions to medical research have made her a global figure in epidemiology and cancer prevention.

šŸ” Conclusion

With over three decades of research in epidemiology and disease prevention, Dr. Hong-Hong Zhu has made groundbreaking contributions in breast and colorectal cancer research. Her innovative approaches to cancer screening and prevention have been life-saving on a global scale. She remains a recognized leader in public health, continuing to inspire through her research, publications, and numerous honors. šŸŒŸ

 

šŸ“ŠšŸ”¬NOTABLE PUBLICATION:

 

  • Combining FITs and HRFQ with colonoscopy improve the cost-effectiveness of a 9-year mass colorectal cancer screening program
    Authors: Cai, S.-R., Huang, Y.-Q., Li, Q.-R., Yang, J.-H., Zheng, S.
    Journal: ESMO Open
    Year: 2024

 

  • Sex difference in alcohol consumption associated with colorectal cancer risk in Quzhou, China: A nested case-control study
    Authors: Lai, S.-M., Zhu, H.-H., Gan, Z.-J., Wang, Z.-C., Liao, X.-F.
    Journal: Preventive Medicine Reports
    Year: 2024

 

  • Antibody responses to an inactivated SARS-CoV-2 vaccine in individuals aged from 50 to 102 years
    Authors: Zhu, H.-H., Sun, G.-Q., Wu, J.-Y., Wang, Z.-C., Liao, X.-F.
    Journal: Frontiers in Immunology
    Year: 2023

Dr. Stavros Melemenidis | Micrometastases | Best Researcher Award

Posted on by Pencis

Dr. Stavros Melemenidis | Micrometastases | Best Researcher Award

Stanford University School of Medicine | United States

Author Profile

Scopus

Orcid id

šŸ“š Biography: Dr. Stavros Melemenidis

šŸŽ“ Education

  • DPhil in Radiation Biology – University of Oxford, Dept. Radiation Oncology, Oxford, UK (2010-2015)
    • Mentors: Prof. Nicola Sibson, Prof. Ruth Muschel
    • Thesis: Development of molecular targeted imaging methods for the detection of lung metastasis and angiogenesis
  • M.Sc. in Radiation Biology – University of Oxford, Dept. Radiation Oncology, Oxford, UK (2009-2010)
  • M.Sc. in Radiometrics – University of Liverpool, Dept. Physics, Liverpool, UK (2008-2009)
  • B.Sc. in Physics: Medical Applications – University of Liverpool, Dept. Physics, Liverpool, UK (2005-2008)
  • A.Eng. in PC Systems and Peripheral Equipment – IIEK Neapoleos, Technical College, Thessaloniki, Greece (1998-2000)
  • Cert. Medical Physics – UCLA, Dept. Radiation Oncology, Los Angeles, CA, USA (2022-2023)

šŸ¢ Current Position

  • Director of Pre-clinical Radiotherapy – Dept. of Radiation Oncology, Stanford University (Jan 2023-present)
  • Research Scientist – Div. of Radiation Therapy, Stanford University (Feb 2020-present)

šŸ”¬ Research Experience & Skills

  • Stanford University, Dept. Radiation Oncology, Stanford, CA
    • Director of Pre-clinical Radiotherapy Core (Jun 2023-present)
      • Calibration of preclinical orthovoltage irradiators
      • Monthly and annual quality checks for dosimetric consistency
      • Innovation in animal radiation shielding via 3D design and additive manufacturing
    • Basic Life Research Scientist at Div. of Radiation Therapy (Jun 2020-present)
      • Pioneering preclinical ultra-high dose-rate (FLASH) irradiation experiments
      • Specializing in 3D-designed radiation shielding for animal safety
      • Expertise in dosimetry using radiochromic film and ion chambers
      • Development of animal models involving tumor implantation and microsurgical techniques
    • Postdoctoral Fellow (Feb 2016-Jun 2020)
      • Advisor: Edward E. Graves
      • Led development of in vivo mouse tumor models integrating imaging, radiotherapy, and immunotherapy
      • Specialized in ultrasound-guided injection techniques
      • Conducted research into immune cell migration with a focus on macrophage imaging
      • Evaluated radioprotective strategies for healthy tissue through drug development
    • Postdoctoral Fellow at University of Oxford, Dept. Radiation Oncology (Jan 2015-Sep 2015)
      • Advisor: Nicola R. Sibson
      • Designed and evaluated innovative imaging probes for metastasis detection and angiogenesis visualization
      • Developed dual MRI/PET probe for metastasis and MRI probe for angiogenesis
      • Managed international research collaboration with Duke University

šŸ“œ Selected Publications

  • In vivo PET detection of lung micrometastasis by targeting endothelial VCAM-1. Int J Mol Sci, 2024.
  • Multi-institutional audit of FLASH and conventional dosimetry with a 3D-printed anatomically realistic mouse phantom. Int J Radiat Oncol Biol Phys, 2023.
  • Exploring deep learning for estimating the isoeffective dose of FLASH irradiation from mouse intestinal histological images. J Radiat Oncol Biol Phys, 2023.
  • Human enteroids as a tool to study conventional and ultra-high dose rate radiation. Integr Biol (Camb), 2023.
  • Improving radiotherapy in immunosuppressive microenvironments by targeting complement receptor C5aR1. J Clin Invest, 2023.

šŸ† Awards & Honors

  • Recognition of Excellent Research: Aegean Conferences: 12th International Conference on Complement Therapeutics, Rhodes, Greece, 2019
  • Poster Prize: Aegean Conferences: 3rd International Conference for Tumor Microenvironment and Cellular Stress, Greece, Mykonos, 2014

šŸ—£ļø Conference Presentations

  • Oral Presentation: Demonstrating FLASH effectiveness against CONV dose rates, 34th ACRO Summit, Orlando, FL, March 2024
  • Poster Presentation: Anatomically Realistic 3D Printed Mouse Phantom for Multi-Institutional Benchmarking of FLASH and CONV Irradiation, 65th ASTRO Annual Meeting San Diego, USA, Oct 2023

šŸ“ž References

  • Prof. Billy W Loo Jr: Professor of Radiation Oncology (Radiation Therapy), Stanford University School of Medicine
  • Prof. Edward E Graves: Associate Professor of Radiation Oncology and Director of Molecular Imaging Program, Stanford University School of Medicine
  • Prof. Frederick M Dirbas: Associate Professor of Surgery (General Surgery), Stanford University School of Medicine

Dr. Stavros Melemenidis is a distinguished figure in radiation oncology, with a profound impact on preclinical radiotherapy and FLASH irradiation research. His contributions to innovative imaging techniques and his dedication to advancing cancer treatment methodologies are reflected in his extensive publication record and numerous accolades.

šŸ“ŠšŸ”¬Notable Publication:

 

 

 

 

Prof. IsabellaCavalcanti – Cancer Science – Best Researcher Award

Posted on by Pencis

Prof. IsabellaCavalcanti - Cancer Science - Best Researcher Award

Federal University of Pernambuco (UFPE) - Brazil

Author Profile

Google ScholarĀ 

Scopus

Orcid

EARLY ACADEMIC PURSUITS

Isabella MacƔrio Ferro Cavalcanti began her academic journey by graduating in Biomedicine from the Federal University of Pernambuco (UFPE). Following this, she pursued a master's degree in Therapeutic Innovation at UFPE, delving into advanced studies in the field. She then proceeded to earn her doctorate in Biotechnology, further refining her expertise in biological sciences.

PROFESSIONAL ENDEAVORS

Dr. Cavalcanti's professional career has been marked by significant accomplishments. She specializes in Clinical Microbiology, obtaining further specialization at the University of Pernambuco (UPE). Currently, she serves as a professor at UFPE, where she contributes to the education and training of future professionals in the field. Her involvement extends to leadership roles within various post-graduate programs, emphasizing her dedication to academic advancement.

CONTRIBUTIONS AND RESEARCH FOCUS ON CANCER SCIENCE

Dr. Cavalcanti's research endeavors are diverse and impactful. As the Head and Researcher of Clinical Microbiology at the Laboratory of Immunopathology Keizo Asami at UFPE (LIKA/UFPE), she spearheads investigations into drug delivery systems and their biological activities. Her research group, MicroNAT, focuses on innovative approaches to combat multi-drug-resistant bacteria and biofilm formation. Through her work, she seeks to advance pharmaceutical nanotechnology and fundamental microbiological understanding.

IMPACT AND INFLUENCE

Isabella MacƔrio Ferro Cavalcanti's contributions have had a profound impact on the fields of pharmaceutical nanotechnology and microbiology. Her research findings contribute to the development of novel therapeutic strategies and the understanding of microbial resistance mechanisms. As a respected member of the Brazilian Society of Microbiology and various scientific committees, her expertise is recognized nationally and internationally.

ACADEMIC CITATIONS

Dr. Cavalcanti's work has garnered significant attention within the academic community, reflected in numerous citations of her research publications. Her contributions to scientific literature serve as a foundation for further exploration and innovation in the fields of biotechnology, microbiology, and drug delivery.

LEGACY AND FUTURE CONTRIBUTIONS

With a strong foundation in academia and research, Dr. Cavalcanti's legacy is marked by her dedication to advancing knowledge and addressing critical healthcare challenges. Her leadership in research groups and academic programs ensures the continued development of future scientists and the pursuit of innovative solutions to complex biomedical problems. As she continues her career, her contributions are poised to further shape the landscape of biomedicine and microbiology, leaving a lasting legacy of excellence and innovation.

NOTABLE PUBLICATIONS

Zein nanoparticles containing ceftazidime and tobramycin: antibacterial activity against Gram-negative bacteria. 2024

Proteomic characterization and biological activities of the mucus produced by the zoanthid Palythoa caribaeorum (Duchassaing & Michelotti, 1860) 2023

Efficacy and non-toxicity of ciclopirox olamine-loaded liposomes against Cryptococcus neoformans clinical isolates. 2023

Gram-negative bacilli carrying mcr gene in Brazil: a pathogen on the rise. 2023

Antibiotic resistance profiles on pathogenic bacteria in the Brazilian environments. 2023

Prof Dr. ClausGarbe – Oncology Management and Prevention – Lifetime achievement Award

Posted on by Pencis

Prof Dr. ClausGarbe - Oncology Management and Prevention - Lifetime achievement Award

University of Tuebingen - Germany

AUTHOR PROFILE

Google Scholar

Scopus

Orcid

EARLY ACADEMIC PURSUITS:

Professor Claus Garbe embarked on his academic journey by obtaining his MD from the Free University of Berlin in 1983. Following this, he pursued board certification in Dermatology and Venereology in 1987. His early academic pursuits laid the foundation for his subsequent groundbreaking work in dermatology and oncology.

PROFESSIONAL ENDEAVORS:

In 1990, Professor Garbe achieved his habilitation, akin to a PhD equivalent, with a focus on the biology of melanoma cells. This marked a significant milestone in his academic career, demonstrating his commitment to advancing the understanding of melanoma, a deadly form of skin cancer. In 1995, he transitioned to Eberhard Karls University, Tuebingen, where he assumed the role of University Professor of Dermatology and Head of the Division of Dermatooncology. This move expanded his scope of influence and provided a platform for furthering his research and clinical endeavors.

CONTRIBUTIONS AND RESEARCH FOCUS ON ONCOLOGY MANAGEMENT AND PREVENTION

Professor Garbe's contributions to the field of dermatology and oncology are extensive and profound. His principal research interests encompass the biology and genetics of melanoma and keratinocyte skin cancers, therapeutic trials in skin diseases, epidemiologic studies, and dermato-histopathology. Through his pioneering research, he has elucidated crucial mechanisms underlying skin cancer development and progression, paving the way for innovative therapeutic approaches and preventive strategies.

IMPACT AND INFLUENCE:

Professor Garbe's impact on the field of dermatologic oncology is unparalleled. His leadership roles in numerous multicenter clinical trials since 1989 have facilitated the translation of research findings into clinical practice, ultimately improving patient outcomes. Moreover, his presidency of the European Association of Dermatologic Oncology (EADO) underscores his influence on a global scale, driving collaboration and innovation in the fight against skin cancer.

ACADEMIC CITATIONS:

With over 800 articles and 17 textbooks to his name, Professor Garbe's scholarly output is prolific. His impressive H-index of 116 points reflects the significant impact of his work within the scientific community. His research findings have been cited extensively, highlighting their relevance and contribution to advancing knowledge in dermatology and oncology.

LEGACY AND FUTURE CONTRIBUTIONS:

Professor Garbe's legacy is characterized by his unwavering dedication to advancing the field of dermatologic oncology. His contributions have not only expanded our understanding of skin cancer but have also shaped clinical practice and guidelines. As he continues to spearhead research efforts and mentor the next generation of scientists and clinicians, his legacy is poised to endure, leaving an indelible mark on the field for years to come.

NOTABLE PUBLICATIONS

Sentinel lymph node biopsy is unreliable in predicting melanoma mortality for both younger and older patients. 2024 (2)

Sentinel lymph node biopsy for lentigo maligna melanoma under local anaesthesia. 2024 (3)

Epidemiology of Keratinocyte Skin Cancer with a Focus on Cutaneous Squamous Cell Carcinoma. 2024 (1)

European consensus-based interdisciplinary guideline for invasive cutaneous squamous cell carcinoma: Part 2. Treatmentā€“Update 2023. 2023 (6)

Contribution of MEK Inhibition to BRAF/MEK Inhibitor Combination Treatment of BRAF-Mutant Melanoma: Part 2 of the Randomized, Open-Label, Phase III COLUMBUS Trial. 2023 (2)

Prof Dr. Nives Pećina-Å laus – Cancer Genetics – Best Researcher Award

Posted on by Pencis

Prof Dr. Nives Pećina-Šlaus - Cancer Genetics - Best Researcher Award

Department of Biology School of Medicine University of Zagreb - Croatia

AUTHOR PROFILEĀ 

Google Scholar

Scopus

Orcid

EARLY ACADEMIC PURSUITS

Nives Pecina-Slaus embarked on her academic journey at the University of Zagreb, where she earned her Bachelor's and Master's degrees in Biology in 1990 and 1992, respectively. Her scholarly pursuits culminated in a Ph.D. in the field of molecular oncology from the Medical School at the University of Zagreb in 1998. During her education, she underwent training at prestigious institutions including the Cold Spring Harbor Laboratory in New York and Georgetown University in Washington DC, USA.

PROFESSIONAL ENDEAVORS

Pecina-Slaus's professional career is distinguished by her role as a tenured professor at the Department of Biology and Head of the Laboratory of Neuro-oncology at the Croatian Institute for Brain Research within the School of Medicine at the University of Zagreb. She has served as the principal investigator on seven scientific projects, demonstrating her leadership in the field. Moreover, her research has yielded significant contributions, with over 100 publications to her credit, including scientific papers, book chapters, and a book. Her primary research interests encompass cancer genetics, the Wnt signaling pathway, epithelial to mesenchymal transition, brain tumorigenesis, tumor suppressor genes, and oncogenes.

CONTRIBUTIONS AND RESEARCH FOCUS ON CANCER GENETICS

Pecina-Slaus's work has contributed extensively to our understanding of neuro-oncology and related fields. Her research has shed light on crucial mechanisms underlying cancer development and progression, particularly in the context of brain tumors. Through her numerous publications, she has disseminated valuable insights into cancer genetics, signaling pathways, and tumor microenvironment dynamics. Her expertise extends to mentorship, where she has guided numerous students in their theses.

IMPACT AND INFLUENCE

Pecina-Slaus's contributions have garnered widespread recognition in the scientific community, as evidenced by her invitations to speak at 25 meetings. Furthermore, her work has had a substantial impact on the academic community, as reflected in her impressive citation metrics. With over 2600 citations on Google Scholar and notable indices on Scopus and Web of Science, she has established herself as a respected authority in her field.

ACADEMIC LEGACY AND FUTURE CONTRIBUTIONS

Pecina-Slaus's legacy is marked by her prolific research output, mentorship of students, and editorial roles in esteemed scientific journals. Her dedication to advancing knowledge in neuro-oncology and related disciplines has earned her numerous awards and accolades, including recognition from the Croatian Medical Association and the Academy of Medical Sciences. Moving forward, she is poised to continue making significant contributions to the field through her research, teaching, and editorial activities, further solidifying her position as a leader in neuro-oncology research.

NOTABLE PUBLICATIONS

Glioma Stem Cellsā€”Features for New Therapy Design. 2024

Genetics in ophthalmology: molecular blueprints of retinoblastoma. 2023 (3)

Wnt Signaling Inhibitors and Their Promising Role in Tumor Treatment. 2023 (6)

Different Approaches to Study Molecular Blueprint and Biological Behavior of Brain Tumors: Editorial to the Special Issue ā€œAdvances in Molecular Genetics of Brain Tumorsā€. 2023

Bilateral Meningioma: A Case Report and Review of the Literature. 2022 (2)

 

 

Prof Dr. Zsuzsanna Suba – Cancer Genetics – Distinguished Cancer Treatment Innovation Award

Posted on by Pencis

Prof Dr. Zsuzsanna Suba - Cancer Genetics - Distinguished Cancer Treatment Innovation Award

National Institute of Oncology, Budapest - Hungary

AUTHOR PROFILE

Orcid

EARLY ACADEMIC PURSUITS

Prof. Dr. Zsuzsanna Suba began her academic journey at Semmelweis University in Budapest, where she earned both MD and PhD degrees. During this time, she also obtained postdoctoral board certification in pathology, laying the foundation for her expertise in cancer research.

PROFESSIONAL ENDEAVORS

After completing her postdoctoral certification, Suba delved into cancer research, initially focusing on the effects of chemotherapeutic agents on cell cultures and experimental animals. Later, she expanded her expertise by gaining scientific graduations in oral pathology and habilitation at the Institute of Oral and Maxillofacial Surgery, Semmelweis University, as well as a certification in oral pathology from the University of Sheffield.

CONTRIBUTIONS AND RESEARCH FOCUS ON CANCER GENETICS

Suba's research has been multifaceted, covering various aspects of cancer development and therapy response. She led a working group that investigated the osseointegration of biomaterials in oral and periodontal tissues and explored metabolic and hormonal aspects of oral cancer. Notably, her research identified insulin resistance and estrogen deficiency as risk factors for oral cancer.At the National Institute of Oncology in Budapest, Suba delved into the correlations among hormonal imbalance, metabolic disorders, and genomic instability in female breast cancer patients.

IMPACT AND INFLUENCE

Suba's work has significantly contributed to our understanding of cancer development and treatment response, particularly in oral and breast cancer. Her identification of novel risk factors and exploration of hormonal and metabolic influences have informed both clinical practice and further research in the field.

ACADEMIC CITATIONS

Suba's contributions to cancer research have garnered recognition and citations within the academic community, solidifying her reputation as an expert in clinical cancer genetics and pathology.

LEGACY AND FUTURE CONTRIBUTIONS

As a professor emeritus, Suba continues to shape the future of cancer research, advocating for new strategies that prioritize DNA stabilization in cancer cases. Her emphasis on supportive cancer care underscores the importance of innovative approaches to enhance patient outcomes and quality of life.

NOTABLE PUBLICATIONS

DNA Damage Responses in Tumors Are Not Proliferative Stimuli, but Rather They Are DNA Repair Actions Requiring Supportive Medical Care. 2024

Compensatory Estrogen Signal Is Capable of DNA Repair in Antiestrogen-Responsive Cancer Cells via Activating Mutations. 2020 (7)

 

Ms. Hao Li – Tumor Immunology – Young Scientist Award

Posted on by Pencis

Ms. Hao Li - Tumor Immunology - Young Scientist Award

First Hospital of China Medical University - China

Author Profile

Scopus

EARLY ACADEMIC PURSUITS

Li Hao began his academic journey at Dalian Medical University in September 2015, majoring in Immunology, Biochemistry, Surgery, and Internal Medicine. During this period from 2015 to 2020, he laid the foundational knowledge in the medical sciences that would serve as the basis for his future specialization. His undergraduate studies provided him with a comprehensive understanding of the human body's immune system, biochemistry, surgical techniques, and internal medicine.Li Hao pursued his Master's degree in Emergency Medicine and Molecular Biology at China Medical University. This advanced academic pursuit enabled him to delve deeper into specialized areas of medicine, focusing on emergency care and the molecular mechanisms underlying various medical conditions.

PROFESSIONAL ENDEAVORS

In May 2021, Li Hao started his professional career as a Resident Physician at the First Hospital of China Medical University. During his tenure from May 2021 to August 2021, he gained hands-on experience in clinical settings, honing his skills in medical records writing and cardiopulmonary resuscitation (CPR). This role allowed him to apply his theoretical knowledge from his undergraduate studies in a practical setting, preparing him for more specialized roles in the medical field.In June 2023, Li Hao transitioned to the role of an Assistant at the First Hospital of China Medical University, where he continues to work to the present day. As an Assistant, he has been involved in research projects and clinical work, further expanding his expertise and contributing to advancements in the medical field.

CONTRIBUTIONS AND RESEARCH FOCUS ON TUMOR IMMUNOLOGY

Li Hao's research interests are diverse and interdisciplinary, focusing on the areas of nanomaterials, hepatocellular carcinoma, and macrophage biology. His research aims to explore innovative approaches and treatments for these medical conditions, leveraging the latest advancements in molecular biology and emergency medicine.

IMPACT AND INFLUENCE

Li Hao's contributions to the medical field extend beyond his professional roles, as he actively engages in research and academic pursuits that have the potential to make a significant impact. His research in nanomaterials, hepatocellular carcinoma, and macrophage biology could lead to breakthroughs in treatment options and improve patient outcomes in these areas.

ACADEMIC SITES

Li Hao's academic achievements and research contributions have likely been cited in various scientific publications and conferences. His interdisciplinary research in nanomaterials, hepatocellular carcinoma, and macrophage biology demonstrates his commitment to advancing medical science and contributing valuable insights to the academic community.

LEGACY AND FUTURE CONTRIBUTIONS

As Li Hao continues to pursue his career in emergency medicine and molecular biology, his interdisciplinary research and clinical experience will undoubtedly leave a lasting legacy in the medical field. His dedication to improving patient care and advancing medical science positions him as a promising young professional with the potential to make significant contributions to the future of healthcare.

NOTABLE PUBLICATIONS

Nanomaterials modulate tumor-associated macrophages for the treatment of digestive system tumors.Ā  2024

Glutamate Chemical Exchange Saturation Transfer (GluCEST) MRI to Evaluate the Rapid Antidepressant Effects of Ketamine in the Hippocampus of Rat Depression Model. 2024 (1)

Preclinical multi-physiologic monitoring of immediate-early responses to diverse treatment strategies in breast cancer by optoacoustic imaging. 2024

Glutamate alterations in the premature infant brain during different gestational ages with glutamate chemical exchange saturation transfer imaging: a pilot study. 2023 (1)

Xenon inhalation attenuates neuronal injury and prevents epilepsy in febrile seizure Sprague-Dawley pups. 2023 (1)

 

Dr. Francesco Raspagliesi – Gynecologic Oncology – Best Researcher Award

Posted on by Pencis

Dr. Francesco Raspagliesi - Gynecologic Oncology - Best Researcher Award

Fondazione IRCCS Istituto nazionale Tumori di Milano - Italy Ā 

Author Profile

Scopus

EARLY ACADEMIC PURSUITS

Francesco Raspagliesi began his academic journey with a Degree in Medicine and Surgery from the University of Catania, Italy, which he completed on March 7, 1981. Following this foundational education, he obtained qualifications to practice medicine in 1981 and specialized in Obstetrics and Gynecology from the University of Catania in 1985 and 1988. These early academic pursuits laid the groundwork for his future professional endeavors in the field of gynecologic oncology.

PROFESSIONAL ENDEAVORS

From 1985 to 1992, Raspagliesi served as a Research Fellow at the Fondazione IRCCS Istituto Nazionale Tumori di Milano. He continued his professional growth at the same institution, becoming a Dirigente Medico di 1Ā° Livello from 1992 to 1999 and advancing to Dirigente Medico di 2Ā° Livello Gynecologic Oncology Unit Director from 1999 to 2019. His long-standing association with the Fondazione IRCCS Istituto Nazionale Tumori di Milano demonstrates his commitment and dedication to the field of gynecologic oncology and patient care.

CONTRIBUTIONS AND RESEARCH FOCUS ON GYNECOLOGIC ONCOLOGY

Throughout his career, Raspagliesi has made significant contributions to the field of Obstetrics and Gynecology. His research and clinical work have focused on gynecologic oncology, particularly in the treatment and management of gynecologic cancers. His expertise and leadership as the Gynecologic Oncology Unit Director have contributed to advancements in the diagnosis, treatment, and care of patients with gynecologic cancers.

IMPACT AND INFLUENCE

As a respected figure in the field of gynecologic oncology, Raspagliesi's work has had a profound impact on patient care, research, and education. His leadership roles and contributions to research have helped shape the way gynecologic cancers are treated and managed, influencing clinical practice and improving patient outcomes.

LEGACY AND FUTURE CONTRIBUTIONS

Francesco Raspagliesi's legacy in the field of Obstetrics and Gynecology is characterized by his dedication to patient care, leadership in gynecologic oncology, and contributions to research and education. His continued commitment to advancing the field through research, mentorship, and clinical practice ensures that his influence will be felt by future generations of gynecologic oncologists.

NOTABLE PUBLICATIONS

Real world data of niraparib in platinum sensitive relapsed ovarian cancer: A multicenter experience of the MITO group.Ā  2024

Sentinel node mapping in high-intermediate and high-risk endometrial cancer: Analysis of 5-year oncologic outcomes. 2024

Reproductive outcomes after conservative treatment in early and advanced stage MOGCTs.Ā  2024

Impact of Cold Ischemia on the Stability ofĀ 1H-MRS-Detected Metabolic Profiles of Ovarian Cancer Specimens. 2024

Concurrent Endometrial Cancer in Women with Atypical Endometrial Hyperplasia: What Is the Predictive Value of Patient Characteristics? (2) 2024

 

 

Prof. Apostolos Zaravinos – Cancer Genetics – Excellence in Research

Posted on by Pencis

Prof. Apostolos Zaravinos - Cancer Genetics - Excellence in Research

European University Cyprus - Cyprus

Author Profile

Google Scholar

Orcid

Scopus

EARLY ACADEMIC PURSUITS

Dr. Apostolos Zaravinos began his academic journey with a B.Sc. in Molecular Biology from the Department of Biology at the University of Crete in 2004. He further pursued his passion for medicine by obtaining his Ph.D. in Medicine from the Medical School of the same university in 2008. These foundational academic pursuits laid the groundwork for his subsequent research and professional endeavors in the field of cancer genetics and molecular biology.

PROFESSIONAL ENDEAVORS

After completing his Ph.D., Dr. Zaravinos embarked on a series of professional roles that enriched his expertise and contributed to the scientific community. He worked as a Research Scientist at the Harris Birthright Research Center for Fetal Medicine at Kingā€™s College Hospital from 2009 to 2010. Subsequently, he performed postdoctoral research in Cancer Genetics at the Molecular Medicine Research Center of the University of Cyprus from 2011 to 2013. He further honed his skills in Immunogenetics and Cancer Genetics during his postdoctoral training at the Department of Laboratory Medicine of the Karolinska Institute from 2013 to 2015.In 2015, Dr. Zaravinos was appointed as an Assistant Professor of Cancer Genetics at the European University Cyprus. He was promoted to the rank of Associate Professor in 2019. He also served as an Associate Professor of Genetics at the Department of Basic Medical Science, College of Medicine (CMED) at Qatar University from 2020 to 2021. These academic positions allowed him to mentor students, lead research projects, and contribute to the advancement of cancer genetics and immunogenetics.

CONTRIBUTIONS AND RESEARCH FOCUS ON CANCER GENETICS

Dr. Zaravinos' research contributions are significant and multifaceted. His primary research aim is to achieve an advanced understanding of carcinogenesis by investigating interactions between genes. He is particularly interested in Cancer Immunogenetics and aims to elucidate how the tumor microenvironment relates to different aspects of tumor biology. His research has focused on examining the immune landscape of inflamed tumors, including colorectal cancer and skin melanoma, using next-generation sequencing approaches.

IMPACT AND INFLUENCE

Dr. Zaravinos has made a substantial impact on the field of cancer genetics and immunogenetics. He has authored over 125 original research articles and 7 book chapters, demonstrating his prolific research output. His work has been cited over 3,600 times, with an h-index of 35, as documented on Scopus. His research findings have contributed to the scientific community's understanding of carcinogenesis, tumor immunology, and the tumor microenvironment.

ACADEMIC CITES

Dr. Zaravinos' research has garnered significant attention and recognition in the scientific community, as evidenced by his high citation count and h-index. His publications have been cited over 3,600 times, highlighting the impact and relevance of his research in the field of cancer genetics and immunogenetics.

LEGACY AND FUTURE CONTRIBUTIONS

Dr. Zaravinos' legacy in the field of cancer genetics and immunogenetics is characterized by his groundbreaking research, mentorship, and contributions to scientific literature. His work has paved the way for future research endeavors aimed at understanding carcinogenesis, tumor immunology, and the tumor microenvironment. As a dedicated researcher and educator, Dr. Zaravinos continues to inspire and influence the next generation of scientists, leaving a lasting impact on the field of cancer genetics and molecular biology. His future contributions are eagerly anticipated as he continues to explore new avenues in cancer research and mentor emerging scientists in the field.

NOTABLE PUBLICATIONS

Regulation of PD-L1 Expression by YY1 in Cancer: Therapeutic Efficacy of Targeting YY1. 2024

Peptide absent sequences emerging in human cancers. 2024

Immune Cytolytic Activity and Strategies for Therapeutic Treatment. 2024

Strand asymmetries across genomic processes. 2023

Tumor mutation burden in the prognosis and response of lung cancer patients to immune-checkpoint inhibition therapies. 2023 (3)